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Abstract:  
Purpose: Cost-effectiveness analyses (CEA) of new technologies typically include ‘background’ 
costs (those associated with supportive care, such as monitoring, concomitant medications and 
staff time) as well as drug costs. In oncology, these are often expensive. The cost-effectiveness 
ratio associated with marginal survival (‘CERMS’) calculates the ratio of background costs to 
QALYs during post-progression. With high background costs, the incremental cost-effectiveness 
ratio (ICER) can become less favourable as survival increases and the ICER moves closer to the 
CERMS, making cost-effectiveness prohibitive.  
This study assessed different methods to determine whether high ICERs are caused by high drug 
costs, high ‘background costs’ or a combination of both and how different approaches can alter 
the impact of background costs on the ICER where the CERMS is close to, or above, the cost-
effectiveness threshold. 
 
Methods: NICE oncology technology appraisals published or updated between October 2012 
and October 2017 were reviewed. An ‘exemplar’ case study was selected, and the CEA was 
replicated. Three modelling approaches were tested on the case study model. 
 
Results: Applying one-off ‘transition’ costs during post-progression reduced the ongoing 
‘incremental’ costs of survival, which meant that the CERMS was substantially reduced and 
problems associated with additional survival were less likely to impact the ICER. Similarly, the 
use of two methods of additional utility weighting for end-of-life cases meant that the CERMS was 
reduced proportionally, again lessening the impact of increased survival. 
 
Conclusion: High ICERs can be caused by factors other than the cost of the drug being 
assessed.  Appropriate measurement of costs and benefits of post-progression can avoid, or 
reduce, some of the challenges associated with the costs of increased survival.  Further research 
is needed to assess how alternative approaches to the measurement and application of 
  3 
background costs and benefits may provide an accurate assessment of the incremental benefits 
of life-extending oncology drugs. 
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Introduction 
Modelling in National Institute for Health and Care Excellence 
Oncology Technology Appraisals 
In England and Wales, oncology drugs are assessed for recommendation for use in the NHS by 
the National Institute for Health and Care Excellence (NICE) via the technology appraisal (TA) 
programme.  TAs review the clinical and economic evidence associated with a new technology, 
with economic evaluation of cost-effectiveness being a key factor in the recommendation made by 
NICE. If the incremental cost-effectiveness ratio (ICER) is £20,000 or less per quality-adjusted life 
year (QALY) gained, a technology is usually judged to be cost-effective 1, although if the technology 
meets end of life criteria the threshold may be increased 2.   
 
Oncology technologies are commonly modelled using partitioned survival models with three health 
states 3. On entry into the model, patients enter the ‘pre-progressed’ health state, typically reflecting 
the time in which patients are receiving the active treatment which may delay further disease 
progression. This period is known as ‘progression free survival’ (PFS). Patients then proceed to 
the ‘post-progressed’ health state (PPS), which reflects the point at which the disease has 
developed beyond the stage where active treatment is beneficial. Patients remain in this state until 
death, the final health state. The rate at which individuals move between the health states in each 
treatment arm is estimated by means of parametric equations derived from clinical trial data, with 
some form of extrapolation function. Costs and QALYs associated with being in each health state 
are applied to the cohort over a set number of cycles, and aggregated to estimate the overall cohort 
costs and QALYs in each treatment arm. 
NICE Technology Appraisal Requirements 
In line with the published NICE manual for the development of NICE guidelines, economic 
evaluations include not only treatment-related costs, but all costs relevant to the disease 4. This 
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includes the ‘background’ or ‘supportive care’ healthcare costs, such as monitoring, concomitant 
medications, staff time, and follow-on treatments (both pharmaceutical and surgical), which may 
change as a result of an intervention, thus being relevant to the economic analysis 1,5. In oncology, 
these background costs can be considerable, and may include expensive treatments such as 
radiotherapy and surgery 6,7. Background costs are typically applied in economic models at a 
constant rate each cycle. 
 
Background costs of disease management are often particularly high in the post-progression stage 
of the disease, when service provision shifts from active treatment using outpatient services, to an 
increased requirement for acute inpatient support. For example, a US study found that in the 6 
months before death, cancer-related acute inpatient care increased from $1,785 per patient at 6 
months before death, to $20,559 1 month before death 6. Subsequently, extending survival and 
increasing a patient’s time in the post-progressed stage can be costly.  In addition, in the later 
stages of disease, health-related quality of life (HRQoL) may be relatively low. Therefore, with 
extended patient survival following the intervention, the higher healthcare costs may outweigh the 
benefits accrued through that survival gain and ultimately, this can decrease an intervention’s 
likelihood of being cost-effective.  
 
The Paradox of the CERMS 
A NICE Decision Support Unit (DSU) paper 8 describes four scenarios, supported by examples of 
TAs, in which clinically effective new technologies may not be considered cost-effective even if it 
were possible to acquire and administer them at zero price. Three of these scenarios describe 
situations in which costs relating to the disease of interest from additional life years gained outweigh 
the QALY benefits accrued in that period, generating a negative net benefit impact. The increased 
incremental cost may be accrued through one, or a combination, of the following: (i) survival gain 
for patients requiring continued resource use to treat ongoing health-care needs, (ii) survival gain 
in the post-progressed health state where costs are high for palliative care and HRQoL is low; or 
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(iii) survival gain in the pre-progressed health state, in which active treatment costs remain high. 
The fourth scenario describes a situation in which the survival gain increases the risk for an 
unrelated high-cost event that would not be experienced by patients in the comparator arm. Again, 
the associated costs outweigh the QALY gain from the increased survival.  No TA was identified 
that demonstrated this scenario.  
 
In oncology treatments that extend overall survival (OS), it is common for much of the survival gain 
to be accrued in the post-progressed health state. We report the cost-effectiveness ratio of marginal 
survival (CERMS), which calculates the ratio of background costs during post-progression to 
background QALYs obtained during the same period. Assuming that the intervention is only used 
to treat patients prior to disease progression (although this assumption may not always hold in 
clinical practice, it is common in economic evaluation), as OS increases, the overall ICER will be 
influenced to a greater extent by the background costs and QALYs associated with the post-
progressed health state, and the ICER value will tend towards the CERMS. If the CERMS exceeds 
the NICE cost-effectiveness threshold, which may happen in cases where PPS background costs 
are high or PPS utility is low, it becomes very difficult or, in some cases impossible, for the 
technology to achieve an ICER below the threshold, and the problem becomes greater, the longer 
that the intervention increases survival.  Whilst this might be a legitimate cause of high ICERs, it is 
often conflated with discussions around drug costs (e.g. patient access schemes). 
 
Study objectives 
This study aimed to disentangle the effects of drug costs and ‘background’ costs on the ICER, 
and to understand how the effect of ‘CERMS’ can vary, under a range of different scenarios, and 
whether these can help to address the issues outlined in the NICE Decision Support Unit 
document. 
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Methods 
Review 
All oncology technology appraisals published or updated by NICE between October 2012 and 
October 2017 were screened for inclusion in the review. Any that reported a conventional late-
stage oncology partitioned survival model were included for data extraction. 
 
From each included TA, the details of the appraisal, the technology and the model included in the 
company submission were extracted. While we understand that NICE decisions are commonly 
made on the basis of the adjusted model presented by the Evidence Review Group (ERG), ERG 
reports typically did not contain adequate granularity for data extraction of model input parameters. 
 
Where possible, the CERMS was calculated for each TA by dividing the monthly cost of post-
progression survival by the monthly QALY gained by being in that state.  Where multiple inputs 
were used in models (eg different utility values for different comparators), an average of all relevant 
values was applied. Where transition costs, or PPS background costs for different stages of PPS, 
were used in models (eg greater costs close to death), the cyclical PPS costs (not one-off transition 
costs) for the first stage of PPS were applied only.  
 
Case Study 
Following data extraction a case study was selected to explore whether alternative approaches 
may be useful in avoiding some of the problems outlined in the DSU report.  To select an exemplar 
appraisal, the following criteria were used: (i) well-reported data available in the submission, (ii) a 
CERMS close to, or above, £20,000, (iii) a technology that was ‘not recommended’ by NICE, (iv) a 
simple three-state partitioned survival model, and (v) a combination therapy (ie associated with 
higher therapy costs). 
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Following selection of a case study, the model was replicated as closely as possible by matching 
inputs to those reported (see Supplement B for full commentary on the model replication). 
 
The case study model was then used to test a variety of scenarios. This paper presents 3 ‘test’ 
scenarios that illustrate instances where conventional modelling approaches may miss important 
aspects of how the costs and benefits associated with marginal survival are implemented. It 
evaluates whether alternative approaches, that may better reflect the true distribution of costs and 
benefits, alleviate the problems associated with background costs. These scenarios (described in 
detail below), were as follows: 
Test Scenario 1: Separation of post-progression background costs into ongoing and one-
off costs. 
Test Scenario 2: Adopting end-of-life criteria using the arbitrary QALY weighting 
approach. 
Test Scenario 3: Adopting end-of-life criteria using the ‘population norm’ weighting 
approach. 
 
The impact of these modelling approaches on the ICER was assessed with reference to the case 
study model as the base case, as well as two different disease scenarios in which the proportion 
of time spent in pre- and post- progression was varied from the base case relative to OS, but 
absolute gains between the treatment and comparator arms were kept stable.  These scenarios 
represent the impact that these modelling approaches might have on drugs with comparative 
treatment benefits, but differing disease trajectories. In Disease Scenario 1, OS was shorter than 
in the base case, with the survival gain equating to approximately 50% of treatment OS, while 
Disease Scenario 2 had longer OS compared with the base case, with survival gain equating to 
approximately 15% of treatment OS. 
 
  9 
Test Scenario 1: separation of post-progression background costs 
In oncology models, background costs are typically applied on a monthly (or cyclical) basis, using 
a constant rate for each period.  This does not necessarily reflect the true distribution of service 
use, whereby some costs are likely to be incurred as one-offs. The impact of adjusting the way 
these are applied was investigated by splitting the total PPS background costs into a combination 
of one-off costs and smaller monthly costs as follows: 
 
Timing of costs 1:  All PPS costs applied at a constant monthly rate. 
Timing of costs 2:  80% of the total PPS cost applied as a one-off cost on transition from 
pre-progression to progression, with the remaining costs spread at a 
constant monthly rate. 
Timing of costs 3:  80% of the total PPS cost applied as a one-off cost on transition from 
PPS to death, with the remaining costs spread at a constant monthly 
rate. 
Timing of costs 4:  40% of the total PPS cost applied as a one-off cost on transition from 
pre-progression to progression, 40% of the total PPS cost applied as a 
one-off cost on transition from PPS to death, with the remaining costs 
spread at a constant monthly rate. 
 
Test Scenario 2: adopting ‘end-of-life’ criteria - arbitrary QALY 
weighting 
To reflect the added value of interventions that extend survival in conditions with a shorter life 
expectancy, NICE allows some modification of the utility gain for those patients. This can be 
approached in different ways. The first method is to weight all QALYs throughout the model so that 
the survival benefit has a greater impact on the ICER. There is little guidance about the extent to 
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which the QALYs can be weighted, however the maximum QALY weighting that may be considered 
‘reasonable’ under certain circumstances, according to NICE DSU guidance, is 2.5 9. 
 
Test Scenario 3: adopting ‘end-of-life’ criteria – population norm 
QALY weighting 
The second approach to weighting the QALY, is to apply population norm utilities to the QALY 
gains achieved during the period of extended survival (as outlined in the NICE Methods Guide). 
Within test scenario 3, this was calculated by multiplying the difference between the utility applied 
during post-progression and the population norm utility, by the mean survival gain in years, to 
generate additional QALYs for the treatment arm. These were discounted at 3.5%, before this 
additional QALY gain was added to the total treatment QALYs. 
 
Analysis 
The above scenarios were compared in order to determine whether or not each approach would 
be likely to avoid the problems outlined in the NICE DSU paper.  Specifically, for each scenario, 
we estimated the CERMS to determine the likely effect of each additional month of survival (ie 
testing whether an additional month of survival, at no extra drug cost, would reduce or increase 
the ICER).  
 
Results 
Review 
Following screening of 40 technology appraisals, 29 were included for data extraction (Table 1; see 
Supplement A for details of exclusions).  
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<<insert Table 1>> 
Case Study 
TA403 was selected as an exemplar case study as the model that best fit our selection criteria (see 
Methods). The model could not be replicated exactly due to insufficient detail included in the 
submission for precise replication of the survival curves.  Model results reported in the company 
submission and those estimated by our replication are reported in full in Supplement B. While total 
and incremental costs were closely replicated, total and incremental QALYs were higher in our 
replication, particularly in the pre-progressed state, reducing the overall ICER. In recognition of this, 
we explored the impact of artificially deflating the utilities to produce a closer model match. The 
pattern of results following the subsequent application of modelling approaches was the same, thus 
this paper reports only the results for the replication in which the original model inputs reported by 
the company submission were used. In addition, the ERG noted that an error in the company 
submission resulted in the application of an effective discount rate of 10.9%.  In our analyses, the 
discount rate was corrected to 3.5% in line with the NICE reference case 5.  Table 2 shows the 
results of the model replication used in the current study as a base case, and to which different 
modelling approaches were applied. 
 
<<insert Table 2>>   
 
The CERMS for this model was £12,721 (with the corrected discount rate). All else being equal, in 
order for the case study treatment to come below the NICE cost-effectiveness threshold of £20,000 
per QALY, a drug cost discount of over 90% would be required. It should be noted that, even in a 
biologically implausible scenario where OS remained at 100% in the treatment arm for the whole 
duration of the model (ie reflecting no deaths across the 15 year time horizon), the ICER remained 
above the £20,000 threshold, at £21,833 per QALY, due to a combination of the drug cost and the 
high ‘background’ cost of living with the disease.  
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Test Scenario 1: separation of post-progression background costs 
In the base case (case study) model, total PPS background costs were £11,059 in the treatment 
arm, and £9,706 in the comparator arm. On average, patients in the treatment arm spent 
approximately 14 months in post-progression, while those in the comparator arm spent 12 months 
in post-progression. 
 
In Disease Scenario 1 (where OS was shorter than the base case), total PPS background costs 
were £3,017 in the treatment arm, and £1,826 in the comparator arm. On average, patients in the 
treatment arm spent approximately 4 months in post-progression, while those in the comparator 
arm spent around 2 months in post-progression. 
 
In Disease Scenario 2 (where OS was longer than in the base case), total PPS background costs 
were £10,015 in the treatment arm, and £8,781 in the comparator arm. On average, patients in the 
treatment arm spent approximately 13 months in post-progression, while those in the comparator 
arm spent around 11 months in post-progression. 
 
Accordingly, where substantial one-off costs were applied (as opposed to spreading the costs 
evenly across all months), monthly background costs were £162, £160 and £157 in the base case, 
disease scenario 1 and disease scenario 2 respectively.  
 
<<insert Table 3>> 
 
Regardless of the timing of the one-off cost, separation of the PPS costs resulted in a 3 to 4% 
reduction in the ICER across all disease scenarios (Table 3). The CERMS was reduced by almost 
75%, from £12,721 to around £3,200 across all disease scenarios. 
 
All else being equal (ie assuming the base case survival inputs), in order for the case study 
treatment to fall below the NICE cost-effectiveness threshold of £20,000 per QALY, a drug cost 
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discount of around 90% would still be required despite these changes. However, in contrast to 
applying the PPS background costs evenly across all months, should OS remain at 100% in the 
treatment arm (ie reflecting no deaths across the 15 year time horizon), the ICER would be below 
the threshold, at between £7,000 and £8,000 per QALY (depending on scenario). In fact, by 
manipulating the hazard ratio between the treatment and comparator OS curves, a HR of 0.4 
applied to all disease scenarios would bring the ICER below £20,000. Again, whilst such a HR may 
be biologically implausible, it is now mathematically possible to achieve a sub-threshold ICER, 
which was not possible in the base case. 
 
Test Scenario 2: adopting ‘end-of-life’ criteria - arbitrary QALY 
weighting 
The maximum QALY weighting recommended according to NICE guidance is 2.5. Even with this 
weighting, a drug price discount of 70% would be required to produce an ICER below £20,000.  In 
cases where the ICER is closer to the threshold, this adjustment may have a greater bearing on 
the NICE appraisal outcome. 
 
Although applying QALY weightings had a greater impact on the ICERs than scenario 1, the CERMS 
was reduced to a lower degree (Table 4), with a maximum reduction of 60% applying extensive 
weightings of 2.5. For the biologically implausible scenario where OS remained at 100% in the 
treatment arm for the whole duration of the model (ie reflecting no deaths across the 15 year time 
horizon), the ICER was below £20,000 with even minimal QALY weightings of 1.1.  
<<insert Table 4>> 
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Test Scenario 3: adopting ‘end-of-life’ criteria – population norm 
QALY weighting 
Regardless of the disease scenario, this modelling approach resulted in an ICER reduction of 25% 
to 26% (Table 5).  This is to be expected, since the QALY gains have simply been inflated in a 
proportional manner.  It is important to note, however, that the CERMS reduced in all scenarios.  
Specifically, the CERMS dropped from £12,721 in the base case to £9,525 whenever the population 
norm utility was applied. In the 100% survival in the treatment arm scenario, this adjustment would 
bring the base case model ICER below the £20,000 threshold, to £17,328 per QALY, with a hazard 
ratio of 0.25 required to remain subthreshold. 
 
<<insert Table 5>> 
Combining modelling approaches 
In addition to the scenarios above being tested individually, combinations of scenarios were also 
tested.  This involved only the changes that made the biggest impact on the ICER and CERMS (ie 
the impact of applying an 80% one-off cost on transition to death in combination with QALY 
weightings). 
 
<<insert Table 6>> 
 
The impact on the ICER of combining the two approaches were slightly greater than with 
adopting the QALY weighting approach alone (Table 6). However, the impact on the CERMS was 
the largest observed, with an 88% reduction even with minimal QALY weightings. As with the 
QALY weighting approach alone, 100% survival in the treatment arm would bring the ICER under 
£20,000 for all weightings. 
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Discussion 
Findings and implications 
This study used an exemplar technology appraisal to explore the impact of a number of different 
modelling scenarios upon the incremental costs and QALYs associated with increased survival in 
oncology.  Although our case study used a partitioned survival model approach, the issues raised 
in this paper would apply to any modelling approach where increased survival is likely to accrue 
substantial additional costs. The analysis suggested that (in the example used), some of the 
problems highlighted by a previous NICE DSU report could be avoided, or at least reduced, by 
appropriately measuring the true costs and benefits of incremental survival.  Specifically, the test 
scenarios showed that, when ‘post progression’ costs are broken down into one-off ‘transition’ and 
variable incremental components, then increased survival tended to be more favorable in terms of 
cost-effectiveness.  Likewise, when the QALYs associated with additional survival were given 
increased weighting, there was less evidence of the problems outlined in the NICE DSU report. 
Therefore, many interesting questions are raised regarding the valuation and quantification of 
quality of life and costs in the stages around the end of a patient’s life.  NICE recommends additional 
weighting for QALYs that are gained in cases where death is imminent, but there is little research 
undertaken to demonstrate society’s true preferences for such weightings.  Similarly, whilst 
aggregated costs are often presented for periods spanning several months, there is little research 
linking the costs with the prognosis of the patient, such that accurate costing predictions could be 
made based on changes in prognosis. 
 
Given that background care costs are not at the control of the companies developing new 
technologies, one could argue that the current approach (including all such costs) is unfair in 
situations where they prevent the technology from being considered cost-effective even at zero 
price. For some submissions, companies may wish to explore the plausibility of options for 
presenting scenario analyses in which the background costs associated with the marginal 
increases in post-progression survival are excluded, in order to better illustrate this issue. In any 
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case, there is a need for greater understanding of this issue by HTA agencies, as if HTA modelling 
requirements prevent effective new treatments from coming to market, the ultimate loser is the 
patient and wider society. 
 
Limitations 
Many of the models reported in the TAs reviewed were complex or poorly reported, limiting our 
ability to calculate the CERMS in many cases. The scenarios tested in this study were applied to a 
case study, and as such may be case study specific; other models may find that the same changes 
have a different impact on the ICER. In addition, it was not possible to replicate the case study 
model exactly. It was deemed, however, that use of the case study model with alternative disease 
scenarios provided a useful illustrative example of the impact of different scenarios. 
A final limitation of the study was that the first scenario tested, in which the total background costs 
associated with the progressed health state were split into one-off and ongoing costs, was not 
evidence-based. The proportion of the total background costs applied as a one-off cost in this study 
was arbitrary, and in our recommendations below we describe the need for further research to 
ensure that the costs and benefits associated with late-stage disease are accurately reflected in 
the model. 
 
Recommendations for future research and decision-making 
In order to better represent the costs and benefits associated with progressed disease in a way 
that is fair, more research is required. One aspect of this would be to investigate the plausibility of 
the traditional approach of applying all background costs in a cyclical fashion, the impact of which 
was explored using arbitrary splits in Scenario 1. It may be that in some oncology indications a 
greater amount of resources are used soon after progression, while in others, the bulk of the cost 
may be accumulated closer to death.  In such cases, it may be more appropriate to include some 
background costs, such as pain relief, as ongoing cyclical costs, and others, such as CT scans, as 
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‘one-offs’. Applying these costs in a way that reflects their true timing may then mean that the 
impact of the one-off costs affects the treatment and comparator arms equally, with the cost 
implications of treatment-related survival gain including only those costs that can be truly described 
as ‘ongoing’. 
 
There are also considerations on the other side of the ICER equation; the measurement of HRQoL. 
Typically single separate utility values are applied to the entire period of pre- and post-progression. 
Disutilities may also be included to measure the impact of adverse events associated with the 
treatment or comparator. However, in practice, HRQoL is unlikely to remain static throughout the 
pre- or post-progressed health state, and the timing of utility measurement for each may impact the 
model. If collected soon after progression, the post-progressed utility value may overestimate true 
utility if the patients’ condition has not deteriorated fully, or underestimate it in situations where 
HRQoL is still negatively affected by ongoing treatment toxicity or anxiety and depression following 
the prognosis. Similar problems may affect the measurement of the true treatment benefits 
associated with pre-progression, particularly in models where adverse event disutilities are applied. 
If utility is measured in a trial population, the impact of adverse events may already be captured in 
the utility value, thus resulting in double-counting HRQoL decrements and ultimately undervaluing 
the benefits of maintaining progression-free survival. Some models submitted to TAs have 
recognized the issue of changing utility by applying different utilities within a particular health state; 
they have been applied on a ‘time-from-death’ basis (TA428 10), or with different utilities applied to 
different stages of supportive treatment (TA406 11).  This is far from common practice, and it would 
be interesting to know the impact of such approaches on the CERMS and the ICER. 
 
Conclusion 
This study demonstrates that high ICERs can be caused by factors other than the cost of the drug 
being assessed.  Furthermore, some of the issues outlined in the NICE DSU paper can be 
avoided, or at least reduced, by appropriately measuring the costs and benefits associated with 
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the late stages of a person’s life.  However, in some cases, the cost-effectiveness of treatments 
may still be prohibited because of excessive ‘background’ costs associated with increased 
survival.  Further research is needed to assess how alternative approaches to the measurement 
and application of background costs and benefits may provide an accurate assessment of the 
incremental benefits of life-extending oncology drugs. 
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Table 1  Details of TAs and CERMS  
TA 
Broad 
indication 
Drug name 
Annual PPS 
background 
costs 
PPS 
utility 
CERMS ICER 
NICE 
Decision 
458 
Breast 
(stage III or 
IV) 
Trastuzumab 
emtansine 
£2,072 0.53 £3,910 
£98,525 to 
£131,473 
R 
423 
Breast 
(stage III or 
IV) 
Eribulin £2,799 0.679 £4,122 
£35,624 to 
£36,244 
CR 
263 
Breast 
(stage IV) 
Bevacizumab 
(with 
capecitabine) 
£9,648 0.496 £19,452 £77,318 NR 
463 
RCC 
(advanced) 
Cabozantinib £2,017 0.777 £2,596 - R 
417 
RCC 
(advanced) 
Nivolumab £3,676 0.663* £5,549 
£42,417 to 
£83,829 
R 
333 
RCC 
(advanced) 
Axitinib £4,147 0.61 £6,798 - R 
405 
Bowel 
(metastatic) 
Trifluridine 
(with tipiracil 
hydrochloride) 
£2,319 0.64 £3,623 £44,032 R 
377 
Prostate 
(metastatic) 
Enzalutamide £37,024* 0.612* £60,497 
£27,076 to 
£95,685 
R 
428 
Lung 
(stage III or 
IV) 
Pembrolizumab £1,853 0.763 £2,429 
£23,424 to 
£49,048 
CR 
447 
Lung 
(stage IV) 
Pembrolizumab £6,545 0.668 £9,798 £44,896 CR 
416 Lung Osimertinib £7,255 0.678 £10,701 - CR 
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(stage III or 
IV) 
406 
Lung 
(stage III) 
Crizotinib £2,327* 0.565* £4,119 - R 
411 
Lung 
(stage III or 
IV) 
Necitumumab £4,016 0.55 £7,302 
£60,133 to 
£119,912 
NR 
403 
Lung 
(stage III or 
IV) 
Ramucirumab 
(with 
docetaxel) 
£11,007 0.599 £18,375 
£84,985 to 
£1,106,497 
NR 
395 
Lung 
(stage III) 
Ceritinib £3,764 0.46 £8,183 £62,456 R 
374 
Lung 
(stage III) 
Erlotinib and 
Gefitinib 
£9,949 0.4734 £21,016 
£15,359 to 
£61,132 
CR 
Erlotinib; 
Gefitinib 
NR 
347 
Lung 
(recurrent or 
metastatic) 
Nintedanib £4,380* 0.638 £6,866 
£27,008 to 
£50,776 
R 
310 
Lung 
(recurrent or 
metastatic) 
Afatinib £18,744* 0.52* £36,046 - CR 
421 
Breast (stage 
III) 
Everolimus - - Incalculable £61,046 R 
432 
RCC 
(metastatic) 
Everolimus - - Incalculable 
£52,261 to 
£58,316 
R 
378 
Bowel 
(advanced) 
Ramucirumab 
(with paclitaxel) 
- 0.587 Incalculable 
£53,830 to 
£188,640 
NR 
307 
Bowel 
(metastatic) 
Aflibercept 
(with irinotecan 
- - Incalculable 
£30,474 to 
£36,294 
NR 
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and 
fluorouracil) 
473 
Head & neck 
(recurrent or 
metastatic) 
Cetuximab 
(with platinum-
based therapy) 
- 0.52 Incalculable - CR 
422 
Lung (stage 
III) 
Crizotinib - 0.61 Incalculable - R 
402 
Lung (stage 
III or IV) 
Pemetrexed - - Incalculable £70,538 CR 
412 
Prostate 
(metastatic) 
Radium-223 
dichloride 
- 
0.47 
and 
0.56 
Incalculable £25,963 CR 
391 
Prostate 
(metastatic) 
Cabazitaxel 
(with 
prednisone) 
- 0.6266 Incalculable £49,327 CR 
259 
Prostate 
(metastatic) 
Abiraterone 
acetate (with 
prednisolone) 
- 0.5 Incalculable 
£52,851 to 
£170,550 
CR 
316 
Prostate 
(metastatic) 
Enzalutamide £1,941 - Incalculable 
£14,795 to 
£102,751 
R 
 
Notes: * indicates instances where multiple inputs were used in models. The CERMS was 
calculated by averaging all relevant utility inputs and applying only ongoing background PPS 
costs (not one-off costs). 
Abbreviations: TA, technology appraisal; PPS, post-progression survival; ICER, incremental 
cost-effectiveness ratio; CERMS, cost-effectiveness ratio(s) of marginal survival; R, 
recommended; CR, conditional recommendation; NR, not recommended. 
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Table 2  Replicated TA403 model results with corrected discount rate 
 Treatment Comparator Incremental 
Costs 
Tx cost - pre-progression £24,412 £1,134 £23,278 
Background: pre-progression £1,689 £1,195 £494 
Background: post-progression £11,059 £9,706 £1,353 
Cost of death £0 £0 £0 
AEs £807 £656 £152 
Total cost £37,968 £12,691 £25,276 
QALYs 
Pre-progression QALYs 0.423 0.299 0.124 
Post-progression QALYs 0.602 0.528 0.074 
AEs -0.003 -0.003 0.000 
Total QALYs 1.022 0.825 0.197 
ICER £128,233 
 
Abbreviations: Tx, treatment; AE, adverse event; QALY, quality adjusted life year; ICER, 
incremental cost-effectiveness ratio. 
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Table 3  Results of Scenario 1 (separation of post-progression background costs) 
Scenario 
Cost 
timings 
PPS 
monthly 
Cost 
Total 
treatment 
costs 
Total 
comparator 
costs 
Incremental 
costs 
ICER CERMS 
B
a
s
e
 c
a
s
e
 
Original £635 £37,968 £12,691 £25,276 £128,233 £12,721 
80% at 
death 
£162 £37,417 £13,267 £24,150 £122,521 
£3,245 
80% at 
progression 
£162 £37,851 £13,632 £24,219 £122,868 
40% at 
death and 
40% at 
progression 
£162 £37,634 £13,450 £24,185 £122,695 
D
is
e
a
s
e
 S
c
e
n
a
ri
o
 1
: 
S
h
o
rt
e
r 
O
S
 
Original £635 £29,059 £4,006 £25,053 £144,878 £12,721 
80% at 
death 
£160 £28,044 £3,810 £24,234 £140,143 
£3,205 
80% at 
progression 
£160 £28,700 £4,548 £24,152 £139,668 
40% at 
death and 
40% at 
progression 
£160 £28,371 £4,179 £24,193 £139,906 
D
is
e
a
s
e
 S
c
e
n
a
ri
o
 2
: 
L
o
n
g
e
r 
O
S
 
Original £635 £39,050 £13,900 £25,150 £133,296 £12,721 
80% at 
death 
£157 £38,392 £14,272 £24,120 £127,839 
£3,145 
80% at 
progression 
£157 £38,674 £14,498 £24,176 £128,137 
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40% at 
death and 
40% at 
progression 
£157 £38,533 £14,385 £24,148 £127,988 
 
Abbreviations: OS, overall survival; PPS, post-progression survival; ICER, incremental cost-
effectiveness ratio; CERMS, cost-effectiveness ratio(s) of marginal survival. 
 
Table 4  Results of Scenario 2 (adopting end-of-life criteria using arbitrary QALY 
weightings) 
 
QALY weighting 
1.00 1.10 1.30 1.50 1.70 1.90 2.10 2.30 2.50 
CERMS for 
all disease 
scenarios 
£12,721 £11,565 £9,786 £8,481 £7,483 £6,695 £6,058 £5,531 £5,088 
 
Notes: As survival gain in pre- and post-progression was equal across all disease scenarios and 
monthly costs were the same, the impact of QALY weighting on the CERMS was the same across 
all scenarios. 
Abbreviations: QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; 
CERMS, cost-effectiveness ratio(s) of marginal survival. 
 
Table 5  Results of Scenario 3 (adopting end-of-life criteria using population norm QALY 
weightings) 
Scenario Change 
PPS 
utility 
“Population 
norm” 
utility 
Mean 
survival 
gain 
Additional 
discounted 
QALYs 
CERMS ICER 
Base  
case 
Original 0.599 - 
4.4 
months 
- £12,721 £128,233 
Adjusted  0.599 0.800 
4.4 
months 
0.067 £9,525 £95,848  
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Disease 
Scenario 
1 
Original 0.599 - 
3.74 
months 
- £12,721 £144,878 
Adjusted 0.599 0.800 
3.74 
months 
0.061 £9,525 £106,978 
Disease 
Scenario 
2 
Original 0.599 - 
4.03 
months 
- £12,721 £133,178 
Adjusted 0.599 0.800 
4.03 
months 
0.062 £9,525 £100,190 
 
Abbreviations: PPS, post-progression survival; QALY, quality-adjusted life year; ICER, 
incremental cost-effectiveness ratio; CERMS, cost-effectiveness ratio(s) of marginal survival. 
 
Table 5  CERMSs by QALY weighting with applied transition costs 
 Base 
case 
Applied transition costs (ie reduced monthly cost of survival) and QALY 
weighting 
1.00 1.10 1.30 1.50 1.70 1.90 2.10 2.30 2.50 
Base 
case 
£12,721 £3,245 £2,950 £2,496 £2,164 £1,909 £1,708 £1,545 £1,411 £1,298 
Disease 
Scenario 
1 
£12,721 £3,205 £2,914 £2,466 £2,137 £1,885 £1,687 £1,526 £1,394 £1,282 
Disease 
Scenario 
2 
£12,721 £3,145 £2,859 £2,419 £2,097 £1,850 £1,655 £1,498 £1,367 £1,258 
 
Abbreviations: QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; 
CERMS, cost-effectiveness ratio(s) of marginal survival. 
